Bayer Avelox Uncomplicated Skin Infection Use Clears FDA
Executive Summary
Bayer is studying Avelox for complicated skin infections, the company said following the approval of the fluoroquinolone for uncomplicated skin infection.
You may also be interested in...
Bayer Contracts 500 Ventiv Reps In Preparation For Avelox I.V. Launch
Bayer has contracted 500 sales reps from Ventiv Health to drive the anticipated launch of Avelox I.V. (moxifloxacin) by the end of the year.
Bayer Contracts 500 Ventiv Reps In Preparation For Avelox I.V. Launch
Bayer has contracted 500 sales reps from Ventiv Health to drive the anticipated launch of Avelox I.V. (moxifloxacin) by the end of the year.
Tequin Labeling Notes In Vitro Activity Vs. Penicillin-Resistant S. Pneumoniae
Labeling for Bristol-Myers Squibb's Tequin discusses the in vitro efficacy of the quinolone antibiotic against penicillin-resistant Streptococcus pneumoniae.